Sun Pharma sees remediation process at erstwhile Ranbaxy facilities as a "time consuming" process even as it aims to bring at least one of the plants to conform to current good manufacturing practice regulations (cGMP) in the current fiscal. In the company's Annual Report for 2015-16, Sun Pharma Managing Director Dilip Shanghvi also remained bullish on generating targeted synergies of USD 300 million by next fiscal on account of its integration with Ranbaxy Laboratories. "We are gradually progressing on the remediation process at the erstwhile Ranbaxy facilities, which were found to be non-compliant in the past. While significant efforts to make these facilities compliant are on, this will be a time-consuming process," Shanghvi said. he company expects to complete the remediation steps in at least one of these facilities in this fiscal, he added. Currently, all the four manufacturing facilities of Ranbaxy — Mohali and Toansa in Punjab, Dewas in Madhya Pradesh and Paonta Sahib in Himachal Pradesh — have been banned by the USFDA from export of drugs to the US market.